Beacon Pharmaceuticals Ltd.’s manufacturing capabilities are aligned to a business strategy of developing and commercializing highest quality products across the globe. Beacon has extensive capabilities to develop and manufacture Recombinant proteins, monoclonal antibodies, pegylated technology platform products and plasma derived products.
Beacon is also the pioneer in introducing Liquid in Hard Gelatin Capsule technology which is safer than soft gel capsule.
The company’s capabilities encompass small-scale to large-scale pegylation, lyophilization, aseptic formulation and fill-finish. With complete aseptic integration, the facility carries-out fill-finish activity for pre-filled syringes, vials and pen-fill for devices.